Whether Zongatinib (Zongatinib) has been included in medical insurance and reimbursement policies and patient cost analysis

Zongertinib (zongertinib) is a new oral small molecule targeted drug mainly used to treat patients with advanced or metastatic cancer related to specific gene mutations. This drug has been approved for marketing in China. However, due to the short time it has been on the market in China, it has not yet been included in the national medical insurance directory. Therefore, patients need to pay for it at their own expense when purchasing it domestically, which is relatively expensive. Due to its strong targeting and significant efficacy, it has high clinical value for patients with specific mutations, but the high cost also puts patients under certain financial pressure.

In the domestic market, due to the limited time to market, the availability of zonatinib is relatively limited, and some patients may need to obtain it through large tertiary hospitals or designated pharmacies. Currently, there are no generic drugs available in China, so patients can only rely on the supply of original drugs. This also means that the procurement channels for drugs are relatively single, and prices may change with market supply fluctuations, requiring patients to plan treatment plans and financial budgets in advance.

In overseas markets, the original drug Zongatinib has been launched. Taking the United States as an example, the price of the original drug is usually over 20 more than 10,000 yuan per box. The price is high and strict prescription and drug purchase procedures need to be followed. There are currently no relevant generic drugs on the market, so overseas patients still need to purchase them through formal channels and use them safely in conjunction with the guidance of medical institutions. In contrast, overseas prices and supply channels are more transparent, but the economic burden is still large.

Overall, zongatinib has not yet been included in medical insurance in China, and patients mainly rely on self-pay. For patients with advanced cancer who meet the criteria for genetic mutations, the clinical benefits are significant, but high costs and channel restrictions may affect accessibility. Patients should fully assess their financial situation and treatment needs before use, and formulate a reasonable medication and follow-up plan under the guidance of a doctor to ensure the safe and effective use of the drug and to reduce economic and treatment risks as much as possible.

Keyword tags: zongatinib, medical insurance, reimbursement policy, targeted drugs, gene matching, non-small cell lung cancer, self-funded drug purchase, overseas original drugs.

References:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zongertinib-non-squamous-nsclc-her2-tkd-activating-mutations